Identification of Myocilin Posttranslational Modifications and Binding Partners Under Static and Glaucoma-Relevant Mechanical Stretch
About the Research Project
Program
Award Type
Standard
Award Amount
$75,000
Active Dates
July 01, 2016 - June 30, 2018
Grant ID
G2016027
Co-Principal Investigator(s)
Matthew Torres, PhD, Georgia Institute of Technology
Goals
Myocilin, a protein molecule associated with two specific forms of glaucoma, is expressed at high levels in the very same eye tissue that appears to malfunction and contribute to ocular hypertension– the most common risk factor—in other types of glaucoma. To this day, the normal function of myocilin in the eye tissue and elsewhere in the body remains unknown. We will use knowledge of the myocilin structure and modern proteomics techniques to identify changes in myocilin and interacting partners under distinct glaucoma-relevant environments. This research will help clarify myocilin function and will lead to new targets for novel anti-glaucoma therapies.
Summary
The aim of this research is to comprehend molecular changes in myocilin under experimental conditions in the lab that mimic glaucoma. Myocilin is closely associated with several forms of glaucoma, including early-onset inherited open angle glaucoma, and steroid-induced glaucoma. Myocilin is also expressed at relatively high levels in the eye tissue called the trabecular meshwork (TM). Dysfunction of the TM is believed to bring about elevated ocular pressure, the most common glaucoma risk factor leading to retinal degeneration and vision loss. We will use modern high resolution mass spectrometry techniques to investigate changes in myocilin isolated from the eye-derived cells that maintain the TM tissue. Results of our experiments will provide new insight into glaucoma-relevant changes that will lead to a better understanding of myocilin-associated glaucoma as well the identification of novel targets for anti-glaucoma therapies more generally.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
National Glaucoma Research
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine